Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Mar;40(3):527–540. doi: 10.1128/aac.40.3.527

Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

E J Arts 1, M A Wainberg 1
PMCID: PMC163153  PMID: 8851566

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbotts J., Bebenek K., Kunkel T. A., Wilson S. H. Mechanism of HIV-1 reverse transcriptase. Termination of processive synthesis on a natural DNA template is influenced by the sequence of the template-primer stem. J Biol Chem. 1993 May 15;268(14):10312–10323. [PubMed] [Google Scholar]
  2. Allain B., Lapadat-Tapolsky M., Berlioz C., Darlix J. L. Transactivation of the minus-strand DNA transfer by nucleocapsid protein during reverse transcription of the retroviral genome. EMBO J. 1994 Feb 15;13(4):973–981. doi: 10.1002/j.1460-2075.1994.tb06342.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arts E. J., Li X., Gu Z., Kleiman L., Parniak M. A., Wainberg M. A. Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J Biol Chem. 1994 May 20;269(20):14672–14680. [PubMed] [Google Scholar]
  4. Arts E. J., Marois J. P., Gu Z., Le Grice S. F., Wainberg M. A. Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA. J Virol. 1996 Feb;70(2):712–720. doi: 10.1128/jvi.70.2.712-720.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Arts E. J., Wainberg M. A. Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother. 1994 May;38(5):1008–1016. doi: 10.1128/aac.38.5.1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Arts E.J., Li Z., Wainberg M.A. Analysis of Primer Extension and the First Template Switch during Human Immunodeficiency Virus Reverse Transcription. J Biomed Sci. 1995 Oct;2(4):314–321. doi: 10.1007/BF02255218. [DOI] [PubMed] [Google Scholar]
  7. Bakhanashvili M., Hizi A. The fidelity of the reverse transcriptases of human immunodeficiency viruses and murine leukemia virus, exhibited by the mispair extension frequencies, is sequence dependent and enzyme related. FEBS Lett. 1993 Mar 15;319(1-2):201–205. doi: 10.1016/0014-5793(93)80067-5. [DOI] [PubMed] [Google Scholar]
  8. Balzarini J., Herdewijn P., De Clercq E. Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem. 1989 Apr 15;264(11):6127–6133. [PubMed] [Google Scholar]
  9. Balzarini J., Karlsson A., Pérez-Pérez M. J., Vrang L., Walbers J., Zhang H., Oberg B., Vandamme A. M., Camarasa M. J., De Clercq E. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology. 1993 Jan;192(1):246–253. doi: 10.1006/viro.1993.1027. [DOI] [PubMed] [Google Scholar]
  10. Basu A., Tirumalai R. S., Modak M. J. Substrate binding in human immunodeficiency virus reverse transcriptase. An analysis of pyridoxal 5'-phosphate sensitivity and identification of lysine 263 in the substrate-binding domain. J Biol Chem. 1989 May 25;264(15):8746–8752. [PubMed] [Google Scholar]
  11. Beard W. A., Stahl S. J., Kim H. R., Bebenek K., Kumar A., Strub M. P., Becerra S. P., Kunkel T. A., Wilson S. H. Structure/function studies of human immunodeficiency virus type 1 reverse transcriptase. Alanine scanning mutagenesis of an alpha-helix in the thumb subdomain. J Biol Chem. 1994 Nov 11;269(45):28091–28097. [PubMed] [Google Scholar]
  12. Bebenek K., Abbotts J., Wilson S. H., Kunkel T. A. Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. J Biol Chem. 1993 May 15;268(14):10324–10334. [PubMed] [Google Scholar]
  13. Bebenek K., Roberts J. D., Kunkel T. A. The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J Biol Chem. 1992 Feb 25;267(6):3589–3596. [PubMed] [Google Scholar]
  14. Bianchi V., Pontis E., Reichard P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem. 1986 Dec 5;261(34):16037–16042. [PubMed] [Google Scholar]
  15. Boulerice F., Bour S., Geleziunas R., Lvovich A., Wainberg M. A. High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol. 1990 Apr;64(4):1745–1755. doi: 10.1128/jvi.64.4.1745-1755.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Boyer J. C., Bebenek K., Kunkel T. A. Unequal human immunodeficiency virus type 1 reverse transcriptase error rates with RNA and DNA templates. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6919–6923. doi: 10.1073/pnas.89.15.6919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Boyer P. L., Ferris A. L., Hughes S. H. Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1. J Virol. 1992 Feb;66(2):1031–1039. doi: 10.1128/jvi.66.2.1031-1039.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Boyer P. L., Tantillo C., Jacobo-Molina A., Nanni R. G., Ding J., Arnold E., Hughes S. H. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4882–4886. doi: 10.1073/pnas.91.11.4882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Buckheit R. W., Jr, Germany-Decker J., Qualls-Goodwin K., Bowdon B. J., Shannon W. M. 3'-Azido-3'-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8361–8365. doi: 10.1073/pnas.89.17.8361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Carroll S. S., Geib J., Olsen D. B., Stahlhut M., Shafer J. A., Kuo L. C. Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate. Biochemistry. 1994 Mar 1;33(8):2113–2120. doi: 10.1021/bi00174a018. [DOI] [PubMed] [Google Scholar]
  21. Chaisson R. E., Allain J. P., Leuther M., Volberding P. A. Significant changes in HIV antigen level in the serum of patients treated with azidothymidine. N Engl J Med. 1986 Dec 18;315(25):1610–1611. doi: 10.1056/NEJM198612183152511. [DOI] [PubMed] [Google Scholar]
  22. Cheng N., Merrill B. M., Painter G. R., Frick L. W., Furman P. A. Identification of the nucleotide binding site of HIV-1 reverse transcriptase using dTTP as a photoaffinity label. Biochemistry. 1993 Aug 3;32(30):7630–7634. doi: 10.1021/bi00081a005. [DOI] [PubMed] [Google Scholar]
  23. Cheng Y. C., Dutschman G. E., Bastow K. F., Sarngadharan M. G., Ting R. Y. Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem. 1987 Feb 15;262(5):2187–2189. [PubMed] [Google Scholar]
  24. Cherrington J. M., Allen S. J., McKee B. H., Chen M. S. Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma. Biochem Pharmacol. 1994 Nov 16;48(10):1986–1988. doi: 10.1016/0006-2952(94)90600-9. [DOI] [PubMed] [Google Scholar]
  25. Chong K. T., Pagano P. J., Hinshaw R. R. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother. 1994 Feb;38(2):288–293. doi: 10.1128/aac.38.2.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Coates J. A., Cammack N., Jenkinson H. J., Jowett A. J., Jowett M. I., Pearson B. A., Penn C. R., Rouse P. L., Viner K. C., Cameron J. M. (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother. 1992 Apr;36(4):733–739. doi: 10.1128/aac.36.4.733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Coates J. A., Cammack N., Jenkinson H. J., Mutton I. M., Pearson B. A., Storer R., Cameron J. M., Penn C. R. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother. 1992 Jan;36(1):202–205. doi: 10.1128/aac.36.1.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Coffin J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995 Jan 27;267(5197):483–489. doi: 10.1126/science.7824947. [DOI] [PubMed] [Google Scholar]
  29. Cohen A., Barankiewicz J., Lederman H. M., Gelfand E. W. Purine and pyrimidine metabolism in human T lymphocytes. Regulation of deoxyribonucleotide metabolism. J Biol Chem. 1983 Oct 25;258(20):12334–12340. [PubMed] [Google Scholar]
  30. Connolly K. J., Hammer S. M. Antiretroviral therapy: reverse transcriptase inhibition. Antimicrob Agents Chemother. 1992 Feb;36(2):245–254. doi: 10.1128/aac.36.2.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. D'Aquila R. T., Johnson V. A., Welles S. L., Japour A. J., Kuritzkes D. R., DeGruttola V., Reichelderfer P. S., Coombs R. W., Crumpacker C. S., Kahn J. O. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med. 1995 Mar 15;122(6):401–408. doi: 10.7326/0003-4819-122-6-199503150-00001. [DOI] [PubMed] [Google Scholar]
  32. Dahbo Y., Eriksson S. On the mechanism of deoxyribonucleoside toxicity in human T-lymphoblastoid cells. Reversal of growth inhibition by addition of cytidine. Eur J Biochem. 1985 Aug 1;150(3):429–434. doi: 10.1111/j.1432-1033.1985.tb09038.x. [DOI] [PubMed] [Google Scholar]
  33. Dahlberg J. E., Mitsuya H., Blam S. B., Broder S., Aaronson S. A. Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2469–2473. doi: 10.1073/pnas.84.8.2469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Dornsife R. E., St Clair M. H., Huang A. T., Panella T. J., Koszalka G. W., Burns C. L., Averett D. R. Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother. 1991 Feb;35(2):322–328. doi: 10.1128/aac.35.2.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Dueweke T. J., Kézdy F. J., Waszak G. A., Deibel M. R., Jr, Tarpley W. G. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem. 1992 Jan 5;267(1):27–30. [PubMed] [Google Scholar]
  36. Dueweke T. J., Pushkarskaya T., Poppe S. M., Swaney S. M., Zhao J. Q., Chen I. S., Stevenson M., Tarpley W. G. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4713–4717. doi: 10.1073/pnas.90.10.4713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. El-Deiry W. S., Downey K. M., So A. G. Molecular mechanisms of manganese mutagenesis. Proc Natl Acad Sci U S A. 1984 Dec;81(23):7378–7382. doi: 10.1073/pnas.81.23.7378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Eron J. J., Jr, Johnson V. A., Merrill D. P., Chou T. C., Hirsch M. S. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother. 1992 Jul;36(7):1559–1562. doi: 10.1128/aac.36.7.1559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Faraj A., Agrofoglio L. A., Wakefield J. K., McPherson S., Morrow C. D., Gosselin G., Mathe C., Imbach J. L., Schinazi R. F., Sommadossi J. P. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs. Antimicrob Agents Chemother. 1994 Oct;38(10):2300–2305. doi: 10.1128/aac.38.10.2300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  41. Fischl M., Galpin J. E., Levine J. D., Groopman J. E., Henry D. H., Kennedy P., Miles S., Robbins W., Starrett B., Zalusky R. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med. 1990 May 24;322(21):1488–1493. doi: 10.1056/NEJM199005243222103. [DOI] [PubMed] [Google Scholar]
  42. Fitzgibbon J. E., Howell R. M., Haberzettl C. A., Sperber S. J., Gocke D. J., Dubin D. T. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. Antimicrob Agents Chemother. 1992 Jan;36(1):153–157. doi: 10.1128/aac.36.1.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Furman P. A., Painter G., Wilson J. E., Cheng N., Hopkins S. Substrate inhibition of the human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6013–6017. doi: 10.1073/pnas.88.14.6013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Gao Q., Gu Z. X., Parniak M. A., Li X. G., Wainberg M. A. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J Virol. 1992 Jan;66(1):12–19. doi: 10.1128/jvi.66.1.12-19.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Gao Q., Gu Z., Parniak M. A., Cameron J., Cammack N., Boucher C., Wainberg M. A. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother. 1993 Jun;37(6):1390–1392. doi: 10.1128/aac.37.6.1390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Gao W. Y., Cara A., Gallo R. C., Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8925–8928. doi: 10.1073/pnas.90.19.8925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Gao W. Y., Johns D. G., Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides. Mol Pharmacol. 1994 Oct;46(4):767–772. [PubMed] [Google Scholar]
  49. Gao W. Y., Shirasaka T., Johns D. G., Broder S., Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest. 1993 May;91(5):2326–2333. doi: 10.1172/JCI116463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Geleziunas R., Arts E. J., Boulerice F., Goldman H., Wainberg M. A. Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages. Antimicrob Agents Chemother. 1993 Jun;37(6):1305–1312. doi: 10.1128/aac.37.6.1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Geleziunas R., Schipper H. M., Wainberg M. A. Pathogenesis and therapy of HIV-1 infection of the central nervous system. AIDS. 1992 Dec;6(12):1411–1426. doi: 10.1097/00002030-199212000-00001. [DOI] [PubMed] [Google Scholar]
  52. Goldman M. E., Nunberg J. H., O'Brien J. A., Quintero J. C., Schleif W. A., Freund K. F., Gaul S. L., Saari W. S., Wai J. S., Hoffman J. M. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6863–6867. doi: 10.1073/pnas.88.15.6863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Goldman M. E., O'Brien J. A., Ruffing T. L., Schleif W. A., Sardana V. V., Byrnes V. W., Condra J. H., Hoffman J. M., Emini E. A. A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors. Antimicrob Agents Chemother. 1993 May;37(5):947–949. doi: 10.1128/aac.37.5.947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Gu Z., Arts E. J., Parniak M. A., Wainberg M. A. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2760–2764. doi: 10.1073/pnas.92.7.2760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Gu Z., Fletcher R. S., Arts E. J., Wainberg M. A., Parniak M. A. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J Biol Chem. 1994 Nov 11;269(45):28118–28122. [PubMed] [Google Scholar]
  56. Gu Z., Gao Q., Fang H., Salomon H., Parniak M. A., Goldberg E., Cameron J., Wainberg M. A. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother. 1994 Feb;38(2):275–281. doi: 10.1128/aac.38.2.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Gu Z., Gao Q., Li X., Parniak M. A., Wainberg M. A. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol. 1992 Dec;66(12):7128–7135. doi: 10.1128/jvi.66.12.7128-7135.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Gupta P., Balachandran R., Ho M., Enrico A., Rinaldo C. Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody. J Virol. 1989 May;63(5):2361–2365. doi: 10.1128/jvi.63.5.2361-2365.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Hamamoto Y., Nakashima H., Matsui T., Matsuda A., Ueda T., Yamamoto N. Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob Agents Chemother. 1987 Jun;31(6):907–910. doi: 10.1128/aac.31.6.907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Hao Z., Cooney D. A., Hartman N. R., Perno C. F., Fridland A., DeVico A. L., Sarngadharan M. G., Broder S., Johns D. G. Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol. 1988 Oct;34(4):431–435. [PubMed] [Google Scholar]
  61. Harmenberg J., Akesson-Johansson A., Vrang L., Cox S. Synergistic inhibition of human immunodeficiency virus replication in vitro by combinations of 3'-azido-3'-deoxythymidine and 3'-fluoro-3'-deoxythymidine. AIDS Res Hum Retroviruses. 1990 Oct;6(10):1197–1202. doi: 10.1089/aid.1990.6.1197. [DOI] [PubMed] [Google Scholar]
  62. Harrington J. A., Reardon J. E., Spector T. 3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA. Antimicrob Agents Chemother. 1993 Apr;37(4):918–920. doi: 10.1128/aac.37.4.918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Hart G. J., Orr D. C., Penn C. R., Figueiredo H. T., Gray N. M., Boehme R. E., Cameron J. M. Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother. 1992 Aug;36(8):1688–1694. doi: 10.1128/aac.36.8.1688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Heidenreich O., Kruhøffer M., Grosse F., Eckstein F. Inhibition of human immunodeficiency virus 1 reverse transcriptase by 3'-azidothymidine triphosphate. Eur J Biochem. 1990 Sep 24;192(3):621–625. doi: 10.1111/j.1432-1033.1990.tb19268.x. [DOI] [PubMed] [Google Scholar]
  65. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995 Jan 12;373(6510):123–126. doi: 10.1038/373123a0. [DOI] [PubMed] [Google Scholar]
  66. Ho H. T., Hitchcock M. J. Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother. 1989 Jun;33(6):844–849. doi: 10.1128/aac.33.6.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Hsieh J. C., Zinnen S., Modrich P. Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J Biol Chem. 1993 Nov 25;268(33):24607–24613. [PubMed] [Google Scholar]
  68. Huang P., Farquhar D., Plunkett W. Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem. 1990 Jul 15;265(20):11914–11918. [PubMed] [Google Scholar]
  69. Huber H. E., McCoy J. M., Seehra J. S., Richardson C. C. Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching. J Biol Chem. 1989 Mar 15;264(8):4669–4678. [PubMed] [Google Scholar]
  70. Izuta S., Saneyoshi M., Sakurai T., Suzuki M., Kojima K., Yoshida S. The 5'-triphosphates of 3'-azido-3'-deoxythymidine and 2', 3'-dideoxynucleosides inhibit DNA polymerase gamma by different mechanisms. Biochem Biophys Res Commun. 1991 Sep 16;179(2):776–783. doi: 10.1016/0006-291x(91)91884-f. [DOI] [PubMed] [Google Scholar]
  71. Jacobo-Molina A., Ding J., Nanni R. G., Clark A. D., Jr, Lu X., Tantillo C., Williams R. L., Kamer G., Ferris A. L., Clark P. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6320–6324. doi: 10.1073/pnas.90.13.6320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Jacques P. S., Wöhrl B. M., Ottmann M., Darlix J. L., Le Grice S. F. Mutating the "primer grip" of p66 HIV-1 reverse transcriptase implicates tryptophan-229 in template-primer utilization. J Biol Chem. 1994 Oct 21;269(42):26472–26478. [PubMed] [Google Scholar]
  73. Johnson M. A., Ahluwalia G., Connelly M. C., Cooney D. A., Broder S., Johns D. G., Fridland A. Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem. 1988 Oct 25;263(30):15354–15357. [PubMed] [Google Scholar]
  74. Johnson M. A., Fridland A. Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. Mol Pharmacol. 1989 Aug;36(2):291–295. [PubMed] [Google Scholar]
  75. Karlsson A., Reichard P., Eckstein F. Hydroxyurea increases the phosphorylation of 3'-fluorothymidine and 3'-azidothymidine in CEM cells. Eur J Biochem. 1989 Dec 22;186(3):689–694. doi: 10.1111/j.1432-1033.1989.tb15261.x. [DOI] [PubMed] [Google Scholar]
  76. Kati W. M., Johnson K. A., Jerva L. F., Anderson K. S. Mechanism and fidelity of HIV reverse transcriptase. J Biol Chem. 1992 Dec 25;267(36):25988–25997. [PubMed] [Google Scholar]
  77. Kellam P., Boucher C. A., Larder B. A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1934–1938. doi: 10.1073/pnas.89.5.1934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Keller P. M., McKee S. A., Fyfe J. A. Cytoplasmic 5'-nucleotidase catalyzes acyclovir phosphorylation. J Biol Chem. 1985 Jul 25;260(15):8664–8667. [PubMed] [Google Scholar]
  79. Klarmann G. J., Schauber C. A., Preston B. D. Template-directed pausing of DNA synthesis by HIV-1 reverse transcriptase during polymerization of HIV-1 sequences in vitro. J Biol Chem. 1993 May 5;268(13):9793–9802. [PubMed] [Google Scholar]
  80. Kohlstaedt L. A., Wang J., Friedman J. M., Rice P. A., Steitz T. A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992 Jun 26;256(5065):1783–1790. doi: 10.1126/science.1377403. [DOI] [PubMed] [Google Scholar]
  81. Kong X. B., Zhu Q. Y., Ruprecht R. M., Watanabe K. A., Zeidler J. M., Gold J. W., Polsky B., Armstrong D., Chou T. C. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine. Antimicrob Agents Chemother. 1991 Oct;35(10):2003–2011. doi: 10.1128/aac.35.10.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Krieg C. J., Ostertag W., Clauss U., Pragnell I. B., Swetly P., Roesler G., Weimann B. J. Increase in intracisternal A-type particles in Friend cells during inhibition of Friend virus (SFFV) release by interferon or azidothymidine. Exp Cell Res. 1978 Oct 1;116(1):21–29. doi: 10.1016/0014-4827(78)90060-5. [DOI] [PubMed] [Google Scholar]
  83. Kunz B. A. Mutagenesis and deoxyribonucleotide pool imbalance. Mutat Res. 1988 Jul-Aug;200(1-2):133–147. doi: 10.1016/0027-5107(88)90076-0. [DOI] [PubMed] [Google Scholar]
  84. Lacey S. F., Larder B. A. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture. Antimicrob Agents Chemother. 1994 Jun;38(6):1428–1432. doi: 10.1128/aac.38.6.1428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Lacey S. F., Reardon J. E., Furfine E. S., Kunkel T. A., Bebenek K., Eckert K. A., Kemp S. D., Larder B. A. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine. J Biol Chem. 1992 Aug 5;267(22):15789–15794. [PubMed] [Google Scholar]
  86. Larder B. A., Coates K. E., Kemp S. D. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol. 1991 Oct;65(10):5232–5236. doi: 10.1128/jvi.65.10.5232-5236.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  88. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  89. Larder B. A., Kemp S. D., Purifoy D. J. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci U S A. 1989 Jul;86(13):4803–4807. doi: 10.1073/pnas.86.13.4803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Larder B. A., Purifoy D. J., Powell K. L., Darby G. Site-specific mutagenesis of AIDS virus reverse transcriptase. 1987 Jun 25-Jul 1Nature. 327(6124):716–717. doi: 10.1038/327716a0. [DOI] [PubMed] [Google Scholar]
  91. Laskin O. L., de Miranda P., Blum M. R. Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex. J Infect Dis. 1989 Apr;159(4):745–747. doi: 10.1093/infdis/159.4.745. [DOI] [PubMed] [Google Scholar]
  92. Lewis W., Meyer R. R., Simpson J. F., Colacino J. M., Perrino F. W. Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU Triphosphate. Biochemistry. 1994 Dec 6;33(48):14620–14624. doi: 10.1021/bi00252a030. [DOI] [PubMed] [Google Scholar]
  93. Li P., Kuiper L. J., Stephenson A. J., Burrell C. J. De novo reverse transcription is a crucial event in cell-to-cell transmission of human immunodeficiency virus. J Gen Virol. 1992 Apr;73(Pt 4):955–959. doi: 10.1099/0022-1317-73-4-955. [DOI] [PubMed] [Google Scholar]
  94. Lin P. F., Samanta H., Rose R. E., Patick A. K., Trimble J., Bechtold C. M., Revie D. R., Khan N. C., Federici M. E., Li H. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis. 1994 Nov;170(5):1157–1164. doi: 10.1093/infdis/170.5.1157. [DOI] [PubMed] [Google Scholar]
  95. Lori F., Malykh A., Cara A., Sun D., Weinstein J. N., Lisziewicz J., Gallo R. C. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science. 1994 Nov 4;266(5186):801–805. doi: 10.1126/science.7973634. [DOI] [PubMed] [Google Scholar]
  96. Martin J. L., Brown C. E., Matthews-Davis N., Reardon J. E. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother. 1994 Dec;38(12):2743–2749. doi: 10.1128/aac.38.12.2743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Martin J. L., Wilson J. E., Furfine E. S., Hopkins S. E., Furman P. A. Biochemical analysis of human immunodeficiency virus-1 reverse transcriptase containing a mutation at position lysine 263. J Biol Chem. 1993 Feb 5;268(4):2565–2570. [PubMed] [Google Scholar]
  98. Martin J. L., Wilson J. E., Haynes R. L., Furman P. A. Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6135–6139. doi: 10.1073/pnas.90.13.6135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Matthes E., Lehmann C., Scholz D., von Janta-Lipinski M., Gaertner K., Rosenthal H. A., Langen P. Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5'-triphosphate in comparison to cellular DNA polymerases alpha and beta. Biochem Biophys Res Commun. 1987 Oct 14;148(1):78–85. doi: 10.1016/0006-291x(87)91078-3. [DOI] [PubMed] [Google Scholar]
  100. McGowan J. J., Tomaszewski J. E., Cradock J., Hoth D., Grieshaber C. K., Broder S., Mitsuya H. Overview of the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 5):S513–S521. doi: 10.1093/clinids/12.supplement_5.s513. [DOI] [PubMed] [Google Scholar]
  101. Merluzzi V. J., Hargrave K. D., Labadia M., Grozinger K., Skoog M., Wu J. C., Shih C. K., Eckner K., Hattox S., Adams J. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990 Dec 7;250(4986):1411–1413. doi: 10.1126/science.1701568. [DOI] [PubMed] [Google Scholar]
  102. Meyerhans A., Vartanian J. P., Hultgren C., Plikat U., Karlsson A., Wang L., Eriksson S., Wain-Hobson S. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol. 1994 Jan;68(1):535–540. doi: 10.1128/jvi.68.1.535-540.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911–1915. doi: 10.1073/pnas.83.6.1911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Mitsuya H., Jarrett R. F., Matsukura M., Di Marzo Veronese F., DeVico A. L., Sarngadharan M. G., Johns D. G., Reitz M. S., Broder S. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2033–2037. doi: 10.1073/pnas.84.7.2033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Mitsuya H., Yarchoan R., Kageyama S., Broder S. Targeted therapy of human immunodeficiency virus-related disease. FASEB J. 1991 Jul;5(10):2369–2381. doi: 10.1096/fasebj.5.10.1712326. [DOI] [PubMed] [Google Scholar]
  107. Montaner J. S., Singer J., Schechter M. T., Raboud J. M., Tsoukas C., O'Shaughnessy M., Ruedy J., Nagai K., Salomon H., Spira B. Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS. 1993 Feb;7(2):189–196. doi: 10.1097/00002030-199302000-00006. [DOI] [PubMed] [Google Scholar]
  108. Nakashima H., Matsui T., Harada S., Kobayashi N., Matsuda A., Ueda T., Yamamoto N. Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro. Antimicrob Agents Chemother. 1986 Dec;30(6):933–937. doi: 10.1128/aac.30.6.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Nunberg J. H., Schleif W. A., Boots E. J., O'Brien J. A., Quintero J. C., Hoffman J. M., Emini E. A., Goldman M. E. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol. 1991 Sep;65(9):4887–4892. doi: 10.1128/jvi.65.9.4887-4892.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. O'Brien W. A., Namazi A., Kalhor H., Mao S. H., Zack J. A., Chen I. S. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol. 1994 Feb;68(2):1258–1263. doi: 10.1128/jvi.68.2.1258-1263.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Olsen J. C., Furman P., Fyfe J. A., Swanstrom R. 3'-Azido-3'-deoxythymidine inhibits the replication of avian leukosis virus. J Virol. 1987 Sep;61(9):2800–2806. doi: 10.1128/jvi.61.9.2800-2806.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Ono K., Ogasawara M., Iwata Y., Nakane H., Fujii T., Sawai K., Saneyoshi M. Inhibition of reverse transcriptase activity by 2',3'-dideoxythymidine 5'-triphosphate and its derivatives modified on the 3' position. Biochem Biophys Res Commun. 1986 Oct 30;140(2):498–507. doi: 10.1016/0006-291x(86)90760-6. [DOI] [PubMed] [Google Scholar]
  113. Orr D. C., Figueiredo H. T., Mo C. L., Penn C. R., Cameron J. M. DNA chain termination activity and inhibition of human immunodeficiency virus reverse transcriptase by carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine triphosphate. J Biol Chem. 1992 Feb 25;267(6):4177–4182. [PubMed] [Google Scholar]
  114. Painter G. R., Aulabaugh A. E., Andrews C. W. A comparison of the conformations of the 5'-triphosphates of zidovudine (AZT) and thymidine bound to HIV-1 reverse transcriptase. Biochem Biophys Res Commun. 1993 Mar 31;191(3):1166–1171. doi: 10.1006/bbrc.1993.1339. [DOI] [PubMed] [Google Scholar]
  115. Painter G. R., Wright L. L., Hopkins S., Furman P. A. Initial binding of 2'-deoxynucleoside 5'-triphosphates to human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem. 1991 Oct 15;266(29):19362–19368. [PubMed] [Google Scholar]
  116. Pantaleo G., Graziosi C., Demarest J. F., Butini L., Montroni M., Fox C. H., Orenstein J. M., Kotler D. P., Fauci A. S. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993 Mar 25;362(6418):355–358. doi: 10.1038/362355a0. [DOI] [PubMed] [Google Scholar]
  117. Parker W. B., White E. L., Shaddix S. C., Ross L. J., Buckheit R. W., Jr, Germany J. M., Secrist J. A., 3rd, Vince R., Shannon W. M. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5'-triphosphates of carbovir, 3'-azido-3'-deoxythymidine, 2',3'-dideoxyguanosine and 3'-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs. J Biol Chem. 1991 Jan 25;266(3):1754–1762. [PubMed] [Google Scholar]
  118. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M. J., Breslin H. J., Raeymaeckers A., Van Gelder J., Woestenborghs R., Heykants J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature. 1990 Feb 1;343(6257):470–474. doi: 10.1038/343470a0. [DOI] [PubMed] [Google Scholar]
  119. Pauwels R., Balzarini J., Schols D., Baba M., Desmyter J., Rosenberg I., Holy A., De Clercq E. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother. 1988 Jul;32(7):1025–1030. doi: 10.1128/aac.32.7.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Perno C. F., Yarchoan R., Cooney D. A., Hartman N. R., Gartner S., Popovic M., Hao Z., Gerrard T. L., Wilson Y. A., Johns D. G. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med. 1988 Sep 1;168(3):1111–1125. doi: 10.1084/jem.168.3.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Perno C. F., Yarchoan R., Cooney D. A., Hartman N. R., Webb D. S., Hao Z., Mitsuya H., Johns D. G., Broder S. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med. 1989 Mar 1;169(3):933–951. doi: 10.1084/jem.169.3.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Pokholok D. K., Gudima S. O., Yesipov D. S., Dobrynin V. N., Rechinsky V. O., Kochetkov S. N. Interactions of the HIV-1 reverse transcriptase 'AZT-resistant' mutant with substrates and AZT-TP. FEBS Lett. 1993 Jul 5;325(3):237–241. doi: 10.1016/0014-5793(93)81080-j. [DOI] [PubMed] [Google Scholar]
  123. Prasad V. R., Lowy I., de los Santos T., Chiang L., Goff S. P. Isolation and characterization of a dideoxyguanosine triphosphate-resistant mutant of human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11363–11367. doi: 10.1073/pnas.88.24.11363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Preston B. D., Poiesz B. J., Loeb L. A. Fidelity of HIV-1 reverse transcriptase. Science. 1988 Nov 25;242(4882):1168–1171. doi: 10.1126/science.2460924. [DOI] [PubMed] [Google Scholar]
  125. Que B. G., Downey K. M., So A. G. Mechanisms of selective inhibition of 3' to 5' exonuclease activity of Escherichia coli DNA polymerase I by nucleoside 5'-monophosphates. Biochemistry. 1978 May 2;17(9):1603–1606. doi: 10.1021/bi00602a004. [DOI] [PubMed] [Google Scholar]
  126. Reardon J. E. Human immunodeficiency virus reverse transcriptase. A kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization. J Biol Chem. 1993 Apr 25;268(12):8743–8751. [PubMed] [Google Scholar]
  127. Reardon J. E. Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry. 1992 May 12;31(18):4473–4479. doi: 10.1021/bi00133a013. [DOI] [PubMed] [Google Scholar]
  128. Reardon J. E., Miller W. H. Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate. J Biol Chem. 1990 Nov 25;265(33):20302–20307. [PubMed] [Google Scholar]
  129. Reichard P. From RNA to DNA, why so many ribonucleotide reductases? Science. 1993 Jun 18;260(5115):1773–1777. doi: 10.1126/science.8511586. [DOI] [PubMed] [Google Scholar]
  130. Remington K. M., Zhu Y. Q., Phillips T. R., North T. W. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase. J Virol. 1994 Feb;68(2):632–637. doi: 10.1128/jvi.68.2.632-637.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Ricchetti M., Buc H. Reverse transcriptases and genomic variability: the accuracy of DNA replication is enzyme specific and sequence dependent. EMBO J. 1990 May;9(5):1583–1593. doi: 10.1002/j.1460-2075.1990.tb08278.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  133. Richman D. D. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother. 1993 Jun;37(6):1207–1213. doi: 10.1128/aac.37.6.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Richman D., Rosenthal A. S., Skoog M., Eckner R. J., Chou T. C., Sabo J. P., Merluzzi V. J. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother. 1991 Feb;35(2):305–308. doi: 10.1128/aac.35.2.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Richman D., Shih C. K., Lowy I., Rose J., Prodanovich P., Goff S., Griffin J. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11241–11245. doi: 10.1073/pnas.88.24.11241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Romero D. L., Busso M., Tan C. K., Reusser F., Palmer J. R., Poppe S. M., Aristoff P. A., Downey K. M., So A. G., Resnick L. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8806–8810. doi: 10.1073/pnas.88.19.8806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Rooke R., Tremblay M., Soudeyns H., DeStephano L., Yao X. J., Fanning M., Montaner J. S., O'Shaughnessy M., Gelmon K., Tsoukas C. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS. 1989 Jul;3(7):411–415. doi: 10.1097/00002030-198907000-00001. [DOI] [PubMed] [Google Scholar]
  138. Rooke R., Tremblay M., Wainberg M. A. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. Virology. 1990 May;176(1):205–215. doi: 10.1016/0042-6822(90)90245-m. [DOI] [PubMed] [Google Scholar]
  139. Rozencweig M., McLaren C., Beltangady M., Ritter J., Canetta R., Schacter L., Kelley S., Nicaise C., Smaldone L., Dunkle L. Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 5):S570–S575. doi: 10.1093/clinids/12.supplement_5.s570. [DOI] [PubMed] [Google Scholar]
  140. Sardana V. V., Emini E. A., Gotlib L., Graham D. J., Lineberger D. W., Long W. J., Schlabach A. J., Wolfgang J. A., Condra J. H. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J Biol Chem. 1992 Sep 5;267(25):17526–17530. [PubMed] [Google Scholar]
  141. Schinazi R. F., Chu C. K., Peck A., McMillan A., Mathis R., Cannon D., Jeong L. S., Beach J. W., Choi W. B., Yeola S. Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother. 1992 Mar;36(3):672–676. doi: 10.1128/aac.36.3.672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Schinazi R. F., Lloyd R. M., Jr, Nguyen M. H., Cannon D. L., McMillan A., Ilksoy N., Chu C. K., Liotta D. C., Bazmi H. Z., Mellors J. W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993 Apr;37(4):875–881. doi: 10.1128/aac.37.4.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Schinazi R. F., McMillan A., Cannon D., Mathis R., Lloyd R. M., Peck A., Sommadossi J. P., St Clair M., Wilson J., Furman P. A. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992 Nov;36(11):2423–2431. doi: 10.1128/aac.36.11.2423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Shih C. K., Rose J. M., Hansen G. L., Wu J. C., Bacolla A., Griffin J. A. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9878–9882. doi: 10.1073/pnas.88.21.9878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Smerdon S. J., Jäger J., Wang J., Kohlstaedt L. A., Chirino A. J., Friedman J. M., Rice P. A., Steitz T. A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3911–3915. doi: 10.1073/pnas.91.9.3911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Smith M. S., Brian E. L., Pagano J. S. Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine. J Virol. 1987 Dec;61(12):3769–3773. doi: 10.1128/jvi.61.12.3769-3773.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Smith M. S., Kessler J. A., Rankin C. D., Pagano J. S., Kurtzberg J., Carter S. G. Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993 Jan;37(1):144–147. doi: 10.1128/aac.37.1.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Sommadossi J. P., Carlisle R., Schinazi R. F., Zhou Z. Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother. 1988 Jul;32(7):997–1001. doi: 10.1128/aac.32.7.997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Soudeyns H., Yao X. I., Gao Q., Belleau B., Kraus J. L., Nguyen-Ba N., Spira B., Wainberg M. A. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother. 1991 Jul;35(7):1386–1390. doi: 10.1128/aac.35.7.1386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. St Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991 Sep 27;253(5027):1557–1559. doi: 10.1126/science.1716788. [DOI] [PubMed] [Google Scholar]
  151. St Clair M. H., Richards C. A., Spector T., Weinhold K. J., Miller W. H., Langlois A. J., Furman P. A. 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother. 1987 Dec;31(12):1972–1977. doi: 10.1128/aac.31.12.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. St Luce S., Arts E., Geleziunas R., Bour S., Wainberg M. A. Infection of human monocyte-derived macrophages by human immunodeficiency virus mediated by cell-to-cell transmission. J Med Virol. 1993 Sep;41(1):71–78. doi: 10.1002/jmv.1890410115. [DOI] [PubMed] [Google Scholar]
  153. Szebeni J., Patel S. S., Hung K., Wahl L. M., Weinstein J. N. Effects of thymidine and uridine on the phosphorylation of 3'-azido-3'-deoxythymidine (zidovudine) in human mononuclear cells. Antimicrob Agents Chemother. 1991 Jan;35(1):198–200. doi: 10.1128/aac.35.1.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. Szebeni J., Wahl S. M., Popovic M., Wahl L. M., Gartner S., Fine R. L., Skaleric U., Friedmann R. M., Weinstein J. N. Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. Proc Natl Acad Sci U S A. 1989 May;86(10):3842–3846. doi: 10.1073/pnas.86.10.3842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Tan C. K., Civil R., Mian A. M., So A. G., Downey K. M. Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate. Biochemistry. 1991 May 21;30(20):4831–4835. doi: 10.1021/bi00234a001. [DOI] [PubMed] [Google Scholar]
  156. Tantillo C., Ding J., Jacobo-Molina A., Nanni R. G., Boyer P. L., Hughes S. H., Pauwels R., Andries K., Janssen P. A., Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol. 1994 Oct 28;243(3):369–387. doi: 10.1006/jmbi.1994.1665. [DOI] [PubMed] [Google Scholar]
  157. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653–5656. doi: 10.1073/pnas.90.12.5653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Tsai C. H., Doong S. L., Johns D. G., Driscoll J. S., Cheng Y. C. Effect of anti-HIV 2'-beta-fluoro-2',3'-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production. Biochem Pharmacol. 1994 Oct 7;48(7):1477–1481. doi: 10.1016/0006-2952(94)90573-8. [DOI] [PubMed] [Google Scholar]
  159. Tsuchihashi Z., Brown P. O. DNA strand exchange and selective DNA annealing promoted by the human immunodeficiency virus type 1 nucleocapsid protein. J Virol. 1994 Sep;68(9):5863–5870. doi: 10.1128/jvi.68.9.5863-5870.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Vartanian J. P., Meyerhans A., Sala M., Wain-Hobson S. G-->A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3092–3096. doi: 10.1073/pnas.91.8.3092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  161. Vince R., Hua M., Brownell J., Daluge S., Lee F. C., Shannon W. M., Lavelle G. C., Qualls J., Weislow O. S., Kiser R. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochem Biophys Res Commun. 1988 Oct 31;156(2):1046–1053. doi: 10.1016/s0006-291x(88)80950-1. [DOI] [PubMed] [Google Scholar]
  162. Wainberg M. A., Gu Z., Gao Q., Arts E., Geleziunas R., Bour S., Beaulieu R., Tsoukas C., Singer J., Montaner J. Clinical correlates and molecular basis of HIV drug resistance. J Acquir Immune Defic Syndr. 1993;6 (Suppl 1):S36–S46. [PubMed] [Google Scholar]
  163. Wakefield J. K., Jablonski S. A., Morrow C. D. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J Virol. 1992 Nov;66(11):6806–6812. doi: 10.1128/jvi.66.11.6806-6812.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Bonhoeffer S., Nowak M. A., Hahn B. H. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995 Jan 12;373(6510):117–122. doi: 10.1038/373117a0. [DOI] [PubMed] [Google Scholar]
  165. West A. B., Roberts T. M., Kolodner R. D. Regulation of the reverse transcriptase of human immunodeficiency virus type 1 by dNTPs. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9720–9724. doi: 10.1073/pnas.89.20.9720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  166. White E. L., Parker W. B., Macy L. J., Shaddix S. C., McCaleb G., Secrist J. A., 3rd, Vince R., Shannon W. M. Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochem Biophys Res Commun. 1989 Jun 15;161(2):393–398. doi: 10.1016/0006-291x(89)92611-9. [DOI] [PubMed] [Google Scholar]
  167. White E. L., Parker W. B., Ross L. J., Shannon W. M. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5'-triphosphates of various anti-HIV nucleoside analogs. Antiviral Res. 1993 Dec;22(4):295–308. doi: 10.1016/0166-3542(93)90039-l. [DOI] [PubMed] [Google Scholar]
  168. Wilson J. E., Martin J. L., Borroto-Esoda K., Hopkins S., Painter G., Liotta D. C., Furman P. A. The 5'-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993 Aug;37(8):1720–1722. doi: 10.1128/aac.37.8.1720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  169. Wu J. C., Warren T. C., Adams J., Proudfoot J., Skiles J., Raghavan P., Perry C., Potocki I., Farina P. R., Grob P. M. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry. 1991 Feb 26;30(8):2022–2026. doi: 10.1021/bi00222a003. [DOI] [PubMed] [Google Scholar]
  170. Wu J., Amandoron E., Li X., Wainberg M. A., Parniak M. A. Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. Interaction with a possible deoxynucleoside triphosphate binding domain. J Biol Chem. 1993 May 15;268(14):9980–9985. [PubMed] [Google Scholar]
  171. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]
  172. Yarchoan R., Mitsuya H., Myers C. E., Broder S. Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 1989 Sep 14;321(11):726–738. doi: 10.1056/NEJM198909143211106. [DOI] [PubMed] [Google Scholar]
  173. Yarchoan R., Mitsuya H., Thomas R. V., Pluda J. M., Hartman N. R., Perno C. F., Marczyk K. S., Allain J. P., Johns D. G., Broder S. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science. 1989 Jul 28;245(4916):412–415. doi: 10.1126/science.2502840. [DOI] [PubMed] [Google Scholar]
  174. Yarchoan R., Perno C. F., Thomas R. V., Klecker R. W., Allain J. P., Wills R. J., McAtee N., Fischl M. A., Dubinsky R., McNeely M. C. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988 Jan 16;1(8577):76–81. doi: 10.1016/s0140-6736(88)90283-8. [DOI] [PubMed] [Google Scholar]
  175. Yarchoan R., Pluda J. M., Perno C. F., Mitsuya H., Broder S. Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. Blood. 1991 Aug 15;78(4):859–884. [PubMed] [Google Scholar]
  176. Zack J. A., Arrigo S. J., Weitsman S. R., Go A. S., Haislip A., Chen I. S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990 Apr 20;61(2):213–222. doi: 10.1016/0092-8674(90)90802-l. [DOI] [PubMed] [Google Scholar]
  177. Zack J. A., Haislip A. M., Krogstad P., Chen I. S. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol. 1992 Mar;66(3):1717–1725. doi: 10.1128/jvi.66.3.1717-1725.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  178. Zhan X., Tan C. K., Scott W. A., Mian A. M., Downey K. M., So A. G. Catalytically distinct conformations of the ribonuclease H of HIV-1 reverse transcriptase by substrate cleavage patterns and inhibition by azidothymidylate and N-ethylmaleimide. Biochemistry. 1994 Feb 15;33(6):1366–1372. doi: 10.1021/bi00172a012. [DOI] [PubMed] [Google Scholar]
  179. Zhang D., Caliendo A. M., Eron J. J., DeVore K. M., Kaplan J. C., Hirsch M. S., D'Aquila R. T. Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1994 Feb;38(2):282–287. doi: 10.1128/aac.38.2.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  180. Zimmerman T. P., Mahony W. B., Prus K. L. 3'-azido-3'-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem. 1987 Apr 25;262(12):5748–5754. [PubMed] [Google Scholar]
  181. de Wolf F., Lange J. M., Goudsmit J., Cload P., de Gans J., Schellekens P. T., Coutinho R. A., Fiddian A. P., van der Noordaa J. Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet. 1988 Feb 20;1(8582):373–376. doi: 10.1016/s0140-6736(88)91179-8. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES